# Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

> **NCT04104399** · PHASE1 · UNKNOWN · sponsor: **Xoc Pharmaceuticals** · enrollment: 32 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** XC101-D13H
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04104399
- **Lead sponsor:** Xoc Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-08
- **Primary completion:** 2022-01-28
- **Final completion:** 2022-03-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104399, "Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04104399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*